ライフサイエンスコーパス: topoisomerase I

1 ds be referred to as 'topological poisons of topoisomerase I'.

2 TATA-dependent transcription such as NC2 and Topoisomerase I.

3 induction by the covalent complex formed by topoisomerase I.

4 or by the formation of poly(ADP-ribosyl)ated topoisomerase I.

5 wn previously to act as poisons of human DNA topoisomerase I.

6 s negative DNA supercoils in the presence of topoisomerase I.

7 of ARF/topoisomerase I complex and DNA-bound topoisomerase I.

8 sitivity to camptothecin by interacting with topoisomerase I.

9 o subunits of DNA gyrase, whereas CT643 is a topoisomerase I.

10 it RNA topoisomerase activity of E. coli DNA topoisomerase I.

11 n the C-terminal domains of Escherichia coli topoisomerase I.

12 st endogenous protein inhibitor specific for topoisomerase I.

13 in and amino acids of the active site of DNA topoisomerase I.

14 Eukaryotic topo II, a type II topoisomerase, is a homodimeric enzyme that solves topol

15 P and other nucleotides in the regulation of topoisomerase I activity in the presence of camptothecin

16 In addition, the described ligand displayed topoisomerase I activity inhibition and self-fluorescenc

17 the active site region of the mutant E. coli topoisomerase I activity shifted the pH for optimal acti

18 ting that these growth defects are caused by topoisomerase I activity.

19 osphorylation, a modification that regulates topoisomerase I activity.

20 somes with camptothecin (CPT)-stabilized DNA-Topoisomerase I adducts activates an ATR-dependent pathw

21 and PBSX were observed in cells depleted of topoisomerase I, an enzyme that relaxes negatively super

22 The interaction activates topoisomerase I, an important target for camptothecin-li

23 relaxation activities of the modified human topoisomerase I analogues having varied steric, electron

24 Covalent topoisomerase I and DNA gyrase complexes are converted i

25 mage, and DNA-protein cross-links (including topoisomerase I and II cleavable complexes) produce stal

26 nduction of DNA cross-linking, inhibition of topoisomerase I and II, and cell-cycle arrest at the S-p

27 e of the protein-protein interaction between topoisomerase I and RNA polymerase during stress respons

28 The functional interaction between topoisomerase I and RNA polymerase has evolved independe

29 a distinct mechanism of interaction between topoisomerase I and RNA polymerase in Mycobacterium tube

30 characterized interaction between bacterial topoisomerase I and RNA polymerase.

31 Here, E1 is shown to bind to human topoisomerase I and stimulate its relaxation activity up

32 consistent with negative feedback control of topoisomerase I and topoisomerase IV expression, which i

33 e evaluated for DNA binding propensities and topoisomerases I and II inhibition as part of their mech

34 DNA gyrase and DNA relaxation by eukaryotic topoisomerases I and II, and E.coli topoisomerase IV.

35 Escherichia coli topoisomerases I and III (Topo I and Topo III) relax neg

36 Escherichia coli topoisomerases I and III can decatenate double-stranded

37 ve for anti-RNA polymerase I/III, 5 for anti-topoisomerase I, and 8 for anticentromere, and 4 were no

38 NA re-ligation, diminishes the expression of topoisomerase I, and enhances the expression of inter al

39 erosis (SSc; scleroderma) patients with anti-topoisomerase I (anti-topo I) antibody who have differen

40 rican patients were more likely to have anti-topoisomerase I (anti-topo I), anti-U1 RNP, and anti-U3

41 era containing autoantibodies against either topoisomerase I (anti-topo I; n = 12), nucleolar protein

42 PB1 alleles using DNA obtained from 318 anti-topoisomerase I antibody-positive patients and 561 healt

43 Anti-topoisomerase I antibody-positive patients were more lik

44 These C-terminal domains of E. coli topoisomerase I are known to interact with RNA polymeras

45 nd Senataxin (SETX), or by the inhibition of topoisomerase I, are actively processed into DNA double-

46 from the 5' side of a nick generated by DNA topoisomerase I at a ribonucleoside monophosphate residu

47 f the DNA cleavage complex formed by type IA topoisomerases is bactericidal.

48 This topoisomerase is being pursued as a novel target for the

49 the widely expressed nuclear protein TOPORS (topoisomerase I-binding arginine/serine rich) are associ

50 We report mutations in the gene for topoisomerase I-binding RS protein (TOPORS) in patients

51 uding ubiquitin-conjugating enzyme 9 (Ubc9); topoisomerase I-binding, arginine/serine-rich, E3 ubiqui

52 YjhX inhibits only topoisomerase I but not topoisomerase III and IV in vitr

53 biomarkers such as carbonic anhydrase IX and topoisomerase I by immunohistochemistry show clear evide

54 s incorporated into the active site of human topoisomerase I by utilizing misacylated suppressor tRNA

55 sult in severely compromised enzymes and DNA topoisomerase I-camptothecin dependent lethality.

56 we report the structure of Escherichia coli topoisomerase I catalytic domain (residues 2-695) in cov

57 Sera were tested for autoantibodies against topoisomerase I, centromere, and RNA polymerase I/III by

58 rotein cross-links, which include stable DNA-topoisomerase I cleavable complexes.

59 ncluding CTP, UTP, and GTP, had no effect on topoisomerase I cleavage and religation activities in th

60 Accumulation of mutant topoisomerase I cleavage complex can lead to SOS inducti

61 single-stranded break associated with mutant topoisomerase I cleavage complex is converted to double-

62 cting Fe-S cluster formation protect against topoisomerase I cleavage complex-mediated cell killing.

63 onse following the accumulation of bacterial topoisomerase I cleavage complex.

64 ibited thymidylate synthase (TS) and trapped topoisomerase I cleavage complexes (Top1CCs), leading to

65 associated with a corresponding increase of topoisomerase I cleavage complexes and were further incr

66 ough the collision of replication forks with topoisomerase I cleavage complexes.

67 SOS induction following topoisomerase I complex accumulation is significantly lo

68 d and decreased levels, respectively, of ARF/topoisomerase I complex and DNA-bound topoisomerase I.

69 tain cancer associated defects affecting ARF/topoisomerase I complex formation could contribute to ce

70 predicted structural similarity to the human topoisomerase I core subdomains I and II (30-IXAla, 30-6

71 repair of substrates mimicking a 3'-blocked topoisomerase I covalent intermediate or an oxidative st

72 solved crystal structure of Escherichia coli topoisomerase I covalently linked to a single-stranded o

73 ogenic and/or lethal DNA damage in which the topoisomerase is covalently linked to the 3'- or 5'-term

74 rved in other previously available bacterial topoisomerase I crystal structures.

75 also results from the action of calf-thymus topoisomerase I (CT Topo I) on a native supercoiled DNA

76 In conclusion, mitochondrial topoisomerase I dampens mitochondrial transcription and

77 ation of covalent complexes formed by mutant topoisomerase I defective in DNA religation.

78 His(nuc)Ala (H182A) mutant actually induced topoisomerase I-dependent cytotoxicity and further enhan

79 Bacterial and archaeal topoisomerase I display selectivity for a cytosine base

80 rase I purified from camptothecin-stabilized topoisomerase I-DNA cleavage complexes in human breast c

81 2/3 chains formed on camptothecin-stabilized topoisomerase I-DNA cleavage complexes.

82 No SUMO-1 peptide was detected in human topoisomerase I-DNA cleavage complexes.

83 Camptothecin-stabilized topoisomerase I-DNA cleavage intermediates in mammalian

84 soquinoline 5 and topotecan (2) bound in the topoisomerase I-DNA covalent complex, as well as molecul

85 plays a major role in the repair of stalled topoisomerase I-DNA covalent complexes.

86 othecins kill mammalian cells by stabilizing topoisomerase I-DNA strand passing intermediates that ar

87 Mutations in topA, encoding topoisomerase I, do not suppress the aberrant positionin

88 The DNA topoisomerase I enzyme of Mycobacterium tuberculosis (Mt

89 features observed for MtTOP1 may allow these topoisomerase I enzymes to carry out physiological funct

90 Among bacterial topoisomerase I enzymes, a conserved methionine residue

91 significantly increased frequencies of anti-topoisomerase I, fibrillarin, and RNP autoantibodies com

92 in M. smegmatis competed with the endogenous topoisomerase I for protein-protein interactions with RN

93 hese mutants are defective in the removal of topoisomerase I from DNA.

94 The encounter of DNA replication forks with topoisomerase I-generated single-stranded DNA breaks res

95 ction, regions of the DNA polymerase and DNA topoisomerase I genes were amplified by PCR, sequenced a

96 ymerase I/III group, +13.4 years in the anti-topoisomerase I group, +11.1 years in the anticentromere

97 Escherichia coli topoisomerase I has an essential function in preventing

98 cal probe, we find that Escherichia coli DNA topoisomerase I has low RNA topoisomerase activity and t

99 OS-inducing mutants of Y. pestis and E. coli topoisomerase I have also been utilized as models to stu

100 increased in MCF7 cells upon treatment with topoisomerase I-II inhibitors.

101 arkedly inhibited in MCF7 and LNCaP cells by topoisomerase I-II inhibitors.

102 Commonly used antitumor agents, such as DNA topoisomerase I/II poisons, kill cancer cells by creatin

103 tance of liberating DNA termini from trapped topoisomerase is illustrated by the progressive neurodeg

104 The inhibitory role of topoisomerase I in mitochondrial transcription is striki

105 ingly different from the stimulatory role of topoisomerase I in nuclear transcription.

106 p3beta differs from that of Escherichia coli topoisomerase I in that the former but not the latter re

107 rDNA and clarifies a structural role of DNA topoisomerase I in the epigenetic regulation of rDNA, in

108 ported to promote the religation activity of topoisomerase I in the presence of camptothecin by itsel

109 ine phosphorylation-dependent coregulator of topoisomerase I in vivo, and it regulates cellular sensi

110 amptothecin, and these drugs also target the topoisomerases I in pathogenic trypanosomes including Le

111 Deficiency or depletion of mitochondrial topoisomerase I increased mitochondrial transcripts, whe

112 in inducing gammaH2AX response and repairing topoisomerase I-induced DNA damage as an alternative pat

113 mining that 2-4-atom lengths are optimal for topoisomerase I inhibition and cytotoxicity.

114 ction by either transcription termination or topoisomerase I inhibition has been shown to increase pa

115 ochondrial inhibitors, intracellular ROS, or topoisomerase I inhibition orchestrates an inflammatory

116 yl side chains display excellent E. coli DNA topoisomerase I inhibition properties with IC50 values <

117 n synthesized and their Escherichia coli DNA topoisomerase I inhibition, binding to B-DNA duplex, and

118 he pyridine series still demonstrated potent topoisomerase I inhibition.

119 RC stress response was also activated by the topoisomerase I inhibitor 7-ethyl-10-hydroxycamptothecin

120 circadian toxicity patterns of irinotecan, a topoisomerase I inhibitor active against colorectal canc

121 hydrogen-bonding interactions in determining topoisomerase I inhibitor binding in the ternary cleavag

122 y, markedly enhanced the cytotoxicity of the topoisomerase I inhibitor camptothecin (CPT).

123 Although the topoisomerase I inhibitor camptothecin also activated AT

124 nd PRC2 exhibit synthetic sensitivity to the topoisomerase I inhibitor Camptothecin and accumulate ga

125 ries, Abbott Park, IL), and the DNA-damaging topoisomerase I inhibitor camptothecin-11 (CPT-11) or SN

126 we examined cells treated with the specific topoisomerase I inhibitor camptothecin.

127 This system contains SN-38-a prodrug of the topoisomerase I inhibitor irinotecan.

128 HER2, a novel enzyme-cleavable linker, and a topoisomerase I inhibitor payload.

129 ) mice are hypersensitive to camptothecin, a topoisomerase I inhibitor that causes DNA damage primari

130 anticancer agent camptothecin (CPT) is a DNA topoisomerase I inhibitor that causes fork collapse and

131 Topotecan (TPT) is a topoisomerase I inhibitor that undergoes reversible, pH-

132 reported that combining (131)I-MIBG with the topoisomerase I inhibitor topotecan induced long-term DN

133 n the present studies, an indenoisoquinoline topoisomerase I inhibitor was conjugated to DUPA via a p

134 various replication inhibitors, including a topoisomerase I inhibitor, camptothecin (CPT).

135 ncer drug, and it is a prodrug of the potent topoisomerase I inhibitor, SN-38 (7-ethyl-10-hydroxycamp

136 raction of a PARP inhibitor, ABT-888, with a topoisomerase I inhibitor, topotecan, in PBMCs, tumor, a

137 ant after treatment with camptothecin, a DNA topoisomerase I inhibitor.

138 Here we encapsulated the topoisomerase-I inhibitor SN-38 in polymeric nanoparticl

139 Etirinotecan pegol is a long-acting topoisomerase-I inhibitor that prolongs exposure to, but

140 an pegol (NKTR-102) is a unique, long-acting topoisomerase-I inhibitor with prolonged systemic exposu

141 rtical neurons from mice, we identify twelve topoisomerase I inhibitors and four topoisomerase II inh

142 Two series of indenoisoquinoline topoisomerase I inhibitors have been prepared to investi

143 p synthesis of a series of clinically active topoisomerase I inhibitors such as NSC 314622, LMP-400,

144 myosin VI transcript were decreased only by topoisomerase I inhibitors.

145 as a strategy for enhancing the efficacy of topoisomerase I inhibitors.

146 Moreover, they acted as topoisomerase I inhibitors.

147 The camptothecin (CPT) Top1 (topoisomerase I) inhibitors exert their anticancer activ

148 es with dual tyrosyl-DNA phosphodiesterase I-topoisomerase I inhibitory activity in one low molecular

149 und 14a was synthesized and found to possess topoisomerase I inhibitory activity that was slightly be

150 topoisomerase I to demonstrate that the ARF/topoisomerase I interaction is regulated by topoisomeras

151 whether Top1mt, the vertebrate mitochondrial topoisomerase, is involved in this process, we studied l

152 Mitochondrial topoisomerase I is a genetically distinct mitochondria-d

153 Bacterial topoisomerase I is a potential target for discovery of n

154 Topoisomerase I is a target for anti-cancer drugs such a

155 Topoisomerase I is a vital enzyme that controls DNA topo

156 DNA topoisomerase I is an essential nuclear enzyme involved

157 ulation of the covalent complex of bacterial topoisomerase I is bactericidal.

158 An elevated level of topoisomerase I is found in many carcinomas, making it a

159 Bacterial topoisomerase I is required for preventing hypernegative

160 Bacterial DNA topoisomerase I is responsible for preventing the hyper-

161 the functional interaction between RecA and topoisomerase I is responsible for RecA-mediated modulat

162 hibited PARP-1/NAD-facilitated religation of topoisomerase I-linked DNA (TLD) in the presence of camp

163 In contrast to the type II enzymes, topoisomerase I maintained approximately 3-fold higher l

164 topoisomerase-mediated DNA scission and that topoisomerase I may be an intrinsically more lethal targ

165 Finally, intercalators enhance topoisomerase I-mediated cleavage of negatively supercoi

166 Sites of topoisomerase I-mediated DNA cleavage do not appear to b

167 hibition can modulate the capacity to repair topoisomerase I-mediated DNA damage in the clinic.

168 The human topoisomerase I-mediated DNA relaxation reaction was stu

169 ancer drugs that act by increasing levels of topoisomerase I-mediated DNA scission.

170 d detect as little as 0.5 SUMO-1 residue per topoisomerase I molecule.

171 duce expression of the corresponding E. coli topoisomerase I mutant (EcTOP-D111N) encoded on a high-c

172 ients with SSc who are positive for anti-DNA topoisomerase I or anticentromere autoantibodies.

173 y itself through the direct interaction with topoisomerase I or by the formation of poly(ADP-ribosyl)

174 patients who had either circulating anti-DNA topoisomerase I (P=7.58x10(-17)/4.84x10(-16)) or anticen

175 of scleroderma induced by immunization with topoisomerase-I peptide-loaded dendritic cells, Mehta et

176 itochondria--polymerase gamma, mitochondrial topoisomerase I, peroxiredoxin 3 and manganese superoxid

177 p14ARF (ARF) and topoisomerase I play central roles in cancer and have re

178 Human topoisomerase I plays an important role in removing posi

179 DDR evoked by the topoisomerase I poison topotecan remained unaffected by

180 boxylesterases (CE) to yield SN-38, a potent topoisomerase I poison.

181 eath after replication stress as a result of topoisomerase I poisoning.

182 to a protein that potentiates the effects of topoisomerase I poisons by binding to damaged DNA and pr

183 veliparib to enhance the cytotoxicity of the topoisomerase I poisons topotecan and camptothecin (CPT)

184 tivity plays a role in protecting cells from topoisomerase I poisons.

185 activity of genotoxic chemotherapy, such as topoisomerase I poisons.

186 es represent a new class of highly cytotoxic topoisomerase I poisons.

187 uted aromathecins as novel antiproliferative topoisomerase I poisons.

188 This could be due to the suppression of topoisomerase I poly(ADP-ribosyl)ation through the compe

189 Both cell lines express wild-type ARF and topoisomerase I proteins at equivalent levels, but H23 t

190 endogenous ubiquitin-family modifications of topoisomerase I purified from camptothecin-stabilized to

191 insertions into the nuclear genome, and with topoisomerase I recognition sites.

192 Human topoisomerase I removes DNA supercoils by clamping a dup

193 A full length structure of E. coli topoisomerase I reported here shows how the C-terminal d

194 ximal to the active site tyrosine of type IA topoisomerases is required for the relaxation of superco

195 member of the conserved Type IA subfamily of topoisomerases, is required for the cell proliferation i

196 rine in Yersinia pestis and Escherichia coli topoisomerase I results in bacterial cell killing due to

197 /topoisomerase I interaction is regulated by topoisomerase I serine phosphorylation, a modification t

198 ants of Yersinia pestis and Escherichia coli topoisomerase I showed that DNA religation can be inhibi

199 sis of purified Y. pestis and E. coli mutant topoisomerase I showed that the Met to Arg substitution

200 Both topoisomerase I siRNA cell lines are resistant to 4NQO,

201 e Top1cc induced by 4NQO, we used two stable topoisomerase I small interfering RNA (siRNA) cell lines

202 bit Mg(2+) dependent religation by bacterial topoisomerase I specifically could be developed into use

203 s a critical gap in the existing ensemble of topoisomerase I structures and provides crucial insights

204 of HIF-1alpha protein by UVC did not require topoisomerase I, suggesting a similar yet distinct mode

205 inhibitor, in combination with topotecan, a topoisomerase I-targeted agent, was carried out to deter

206 agent that produces oxidative DNA damage, or topoisomerase I-targeted drugs (camptothecin and a nonca

207 ing technique to rapidly identify eukaryotic topoisomerase I targeting agents.

208 Topoisomerase I targeting poisons may be particularly ef

209 cells, which express a serine phosphorylated topoisomerase I that complexes with ARF, ectopic overexp

210 mutations in ribonuclease H, senataxin, and topoisomerase I that resolve RNA-DNA hybrids lead to inc

211 rase III is a more efficient decatenase than topoisomerase I, the opposite is true for DNA relaxation

212 is important to characterize the ability of topoisomerase I to cleave positively supercoiled DNA.

213 The ability of H23 topoisomerase I to complex with ARF can be restored by t

214 er cell lines and purified recombinant human topoisomerase I to demonstrate that the ARF/topoisomeras

215 such as the 3'-phosphotyrosyl linkage of DNA topoisomerase I to DNA.

216 The method is based on genetic tagging of topoisomerase I to immobilize the enzyme on a solid surf

217 phodiesterase-1 protects cells from abortive topoisomerase I (Top1) activity by hydrolyzing the 3'-ph

218 These deletion events are dependent on DNA topoisomerase I (Top1) and are initiated by Top1 incisio

219 In the absence of both topoisomerase I (Top1) and topoisomerase II (Top2) activ

220 The DNA-relaxing enzyme topoisomerase I (Top1) can be inhibited by heterocyclic

221 ch as DNA replication and transcription, DNA topoisomerase I (Top1) catalyzes the relaxation of DNA s

222 In eukaryotes, DNA topoisomerase I (Top1) catalyzes the relaxation of super

223 Ribonuclease activity of topoisomerase I (Top1) causes DNA nicks bearing 2',3'-cy

224 tyrosyl bonds resulting from the trapping of topoisomerase I (Top1) cleavage complexes.

225 DNA topoisomerase I (TOP1) has an important role in maintain

226 Topoisomerase I (Top1) has been shown to be coupled with

227 The inhibition of DNA topoisomerase I (Top1) has proven to be a successful app

228 The biological functions of nuclear topoisomerase I (Top1) have been difficult to study beca

229 the repair of damaged DNA resulting from the topoisomerase I (Top1) inhibitor camptothecin and a vari

230 gically transported from the indolocarbazole topoisomerase I (Top1) inhibitor class to the indenoisoq

231 The topoisomerase I (TOP1) inhibitor irinotecan triggers cel

232 Camptothecin (CPT), a topoisomerase I (TOP1) inhibitor, exhibits anti-tumor ac

233 ives, topotecan and irinotecan, are specific topoisomerase I (Top1) inhibitors and potent anticancer

234 Indenoisoquinoline topoisomerase I (Top1) inhibitors are a novel class of a

235 Indenoisoquinoline topoisomerase I (Top1) inhibitors are a novel class of a

236 Novel topoisomerase I (Top1) inhibitors are in clinical develo

237 The compounds were designed as topoisomerase I (Top1) inhibitors based on the indenoiso

238 he biological activity of indenoisoquinoline topoisomerase I (Top1) inhibitors can be greatly enhance

239 A series of 7-azaindenoisoquinoline topoisomerase I (Top1) inhibitors have been prepared to

240 Hydroxylated analogues of the anticancer topoisomerase I (Top1) inhibitors indotecan (LMP400) and

241 The aromathecin or "rosettacin" class of topoisomerase I (top1) inhibitors is effectively a "comp

242 e study of a series of azaindenoisoquinoline topoisomerase I (Top1) inhibitors is reported.

243 mocamptothecins (hCPTs) are a novel class of topoisomerase I (Top1) inhibitors with enhanced chemical

244 entify predictors of cancer cell response to topoisomerase I (Top1) inhibitors, a widely used class o

245 DNA interstrand cross-linking (ICL) agents, topoisomerase I (TOP1) inhibitors, and in Holliday junct

246 In search for a novel chemotype to develop topoisomerase I (Top1) inhibitors, the pyrazolo[1,5-a]qu

247 The 7-azaindenoisoquinolines are cytotoxic topoisomerase I (Top1) inhibitors.

248 ave synthesized indenoisoquinolines as novel topoisomerase I (Top1) inhibitors.

249 ntaining wild-type and mutant alleles of DNA topoisomerase I (TOP1) into the haploid yeast gene-disru

250 ccharomyces cerevisiae, become unstable when topoisomerase I (Top1) is disrupted.

251 Topoisomerase I (Top1) is known to relax DNA supercoilin

252 (432)R) enhanced cell sensitivity to the DNA topoisomerase I (Top1) poison camptothecin.

253 Such linkages form in vivo when topoisomerase I (Top1) processes DNA.

254 Topoisomerase I (Top1) regulates DNA supercoiling and is

255 Topoisomerase I (Top1) relaxes DNA supercoiling by formi

256 ow rapid recruitment, within minutes, of DNA topoisomerase I (TOP1) to a large cohort of AR-regulated

257 transcription-associated damage in yeast is Topoisomerase I (Top1), an enzyme that removes torsional

258 ngle CrA-PdG adduct can form crosslinks with topoisomerase I (Top1), both directly and indirectly.

259 ver, in a RNase H2 knock-out yeast strain, a topoisomerase I (Top1)-dependent mutator effect develops

260 Reversible topoisomerase I (Top1)-DNA cleavage complexes are the ke

261 Reversible topoisomerase I (Top1)-DNA cleavage complexes are the ke

262 lymerase II, Rpb1, in response to stabilized topoisomerase I (Top1)-DNA cleavage complexes.

263 ellular enzyme that repairs the irreversible topoisomerase I (Top1)-DNA complexes and confers chemoth

264 A phosphodiesterase I (TDP1) repairs stalled topoisomerase I (Top1)-DNA covalent complexes and has be

265 This type of linkage is found at stalled topoisomerase I (Top1)-DNA covalent complexes, and TDP1

266 ety and has been implicated in the repair of topoisomerase I (Top1)-DNA covalent complexes.

267 Base damage and topoisomerase I (Top1)-linked DNA breaks are abundant fo

268 s otherwise highly homologous to the nuclear topoisomerase I (Top1).

269 Mitochondrial topoisomerase I (TOP1MT) is a type IB topoisomerase enco

270 Mitochondrial topoisomerase I (Top1mt) is a type IB topoisomerase pres

271 n nuclei and mitochondria, and mitochondrial topoisomerase I (Top1mt) is the only DNA topoisomerase s

272 opoisomerase in vertebrates is mitochondrial topoisomerase I (Top1mt).

273 DNA topoisomerase I (Top1p) catalyzes the relaxation of supe

274 Escherichia coli topoisomerase I (TopA), a regulator of global and local

275 mary cellular target of YjhX was found to be topoisomerase I (TopA), inhibiting both DNA replication

276 the spatiotemporal recruitment of GFP-tagged topoisomerase I (TopI) to sites of localized DNA damage

277 Topoisomerase I (Topo I) and Topo II inhibitors can sele

278 to camptothecin (CPT), impaired CPT-induced topoisomerase I (Topo I) degradation and ubiquitination,

279 Using an NKX3.1 affinity column, we isolated topoisomerase I (Topo I) from a PC-3 prostate cancer cel

280 Human DNA topoisomerase I (topo I) is an essential mammalian enzym

281 Topoisomerase I (topo I) is needed for efficient initiat

282 Topoisomerase I (topo I) is required for the proper init

283 e results of a phase I clinical trial of the topoisomerase I (Topo I) poison CPT-11 followed by the c

284 sor, p14ARF (ARF) is a positive regulator of topoisomerase I (topo I), a central enzyme in DNA metabo

285 cancer drugs slow the religation step of DNA topoisomerase I (topo I).

286 nteraction between the C-terminal domains of topoisomerase I (TopoI-CTDs) and the beta' subunit of RN

287 Presently it is shown that in addition to topoisomerase I, topopyrones A-D also act as poisons of

288 Promoter analysis showed that each topoisomerase is transcribed from its own operon by the

289 Acute depletion of mitochondrial topoisomerase I triggered neither a nuclear mito-biogeni

290 ase I proteins at equivalent levels, but H23 topoisomerase I, unlike that of H358 cells, is largely d

291 Mitochondrial topoisomerase I was co-immunoprecipitated with mitochond

292 The interaction between E1 and topoisomerase I was mapped to the E1 DNA binding domain

293 herichia coli expressing SOS-inducing mutant topoisomerase I was utilized to demonstrate that covalen

294 Because indolicidin can also inhibit topoisomerase I, we believe that multiple actions at the

295 titutions at the TOPRIM glycine of Y. pestis topoisomerase I were examined.

296 Mutants of recombinant Yersinia pestis topoisomerase I with hydrophobic substitutions at this p

297 The association of topoisomerase I with RNA polymerase during transcription

298 In depth biochemical analysis of E. coli topoisomerase I with the corresponding Arg-321 mutation

299 opy-number plasmid clones of Yersinia pestis topoisomerase I (YpTOP) with Asp-to-Asn substitution at

300 with arginine in recombinant Yersinia pestis topoisomerase I (YTOP) was the only substitution at this